Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EURAP & Development
NL-OMON41629Not yet recruiting
- Sponsor
- SEIN
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Single-blind trial of carbamazepine, lamotrigine, valproic acid and levetiracetam in epilepsy (4 arms), sponsored by SEIN. Primary endpoints: Neurocognitive outcomes and Child psychiatric and behavioral outcomes. Planned start Oct 2014; status: not yet recruiting.
02
Drugs
carbamazepinelamotriginevalproic acidlevetiracetam
03
Conditions
epilepsy
Beyond the preview
Go deeper on NL-OMON41629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41629.